Washington, D.C. — More than 50 conservative and free-market leaders signed a letter urging Congress to reject efforts to codify President Donald Trump’s “most favored nation” (MFN) drug pricing policy into federal law.
The letter argues that adopting MFN pricing, which ties certain U.S. prescription drug prices to the lowest prices paid in other developed countries, would amount to importing “socialist price controls” and could undermine pharmaceutical innovation. Signatories include Grover Norquist of Americans for Tax Reform, Stephen Moore of Unleash Prosperity Now, Phil Kerpen of American Commitment, and Pete Sepp of the National Taxpayers Union, among others.
Trump’s executive order directs federal officials to negotiate with drug manufacturers so that U.S. prices for select medications do not exceed the lowest global price. The administration has announced agreements with multiple pharmaceutical companies and has urged lawmakers to make the policy permanent through legislation.
A bipartisan group of House members previously introduced a bill to codify the order’s provisions. Opponents argue the policy could reduce research and development investment and lead to potential drug shortages. Supporters contend it addresses disparities in international drug pricing and reduces costs for American patients.
Sources:
Discover more from News Facts Network
Subscribe to get the latest posts sent to your email.
